PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 27 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Soy phosphatidylinositol (PI) was shown to raise plasma HDL-cholesterol and apolipoprotein A-I levels and reduce triglyceride levels in humans [PMID:18311664].
A comparator beverage formulated with soy phospholipid and palm/coconut oil was used as a control; no adverse effects were reported in participants with metabolic syndrome [PMID:37513677].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 18311664 (2008) — Phospholipids as cardiovascular therapeutics. · Current opinion in investigational drugs (London, England : 2000)
- 2.PMID: 36338387 (2021) — Characterization of milk and soy phospholipid liposomes and inflammation in 3T3-L1 adipocytes. · JDS communications
- 3.PMID: 12841798 (2003) — Safety and pharmacokinetics of an endotoxin-binding phospholipid emulsion. · The Annals of pharmacotherapy
- 4.PMID: 37815121 (2023) — Improving the Physicochemical Stability of Soy Phospholipid-Stabilized Emulsions Loaded with Lutein by the Addition of Sphingomyelin and Cholesterol: Inspired by a Milk Fat Globule Membrane. · Journal of agricultural and food chemistry
- 5.PMID: 33304099 (2020)